Drug intelligence / Profile preview

NovRF

Development stage: Unknown
Lead developer: NovMetaPharma
Modality: Small Molecules

Overview

NovRF is a small molecule drug under development by NovMetaPharma for the treatment of retroperitoneal fibrosis. It is part of the company's pipeline targeting metabolic and fibrotic diseases, including other candidates for diabetes, obesity, kidney disease, and general fibrosis. The specific mechanism of action and molecular target for NovRF have not been publicly disclosed as of June 2025. The drug has reached Phase 1/2 clinical trials for retroperitoneal fibrosis[1][2][5].

Beyond the preview

Go deeper on NovRF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovRF.

Explore the full profile